Advertisement
Screener

NIAGEN BIOSCIENCE, INC. (NAGE) Selling Expense

2.8 / 5 stars · 68/120 Roast Me

NIAGEN BIOSCIENCE, INC. Selling Expense

NIAGEN BIOSCIENCE, INC. (NAGE) reported Selling Expense of $3.07 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:SellingExpense · last filed 2026-08-04

  • NIAGEN BIOSCIENCE, INC. selling expense for the quarter ending 2026-06-30 was $3.07M, a 11.06% increase year-over-year.
  • NIAGEN BIOSCIENCE, INC. selling expense for the quarter ending 2026-03-31 was $2.87M, a 7.59% increase year-over-year.
  • NIAGEN BIOSCIENCE, INC. selling expense for the quarter ending 2025-12-31 was $2.92M, a 4.17% increase year-over-year.
  • NIAGEN BIOSCIENCE, INC. selling expense for the quarter ending 2025-09-30 was $2.90M, a 22.32% increase year-over-year.
  • NIAGEN BIOSCIENCE, INC. selling expense for fiscal 2025 was $11.26M, a 14.61% increase from fiscal 2024.
  • NIAGEN BIOSCIENCE, INC. selling expense for fiscal 2024 was $9.82M, a 11.42% increase from fiscal 2023.
  • NIAGEN BIOSCIENCE, INC. selling expense for fiscal 2023 was $8.81M.
Period endSelling Expense 3 monthSelling Expense 6 monthSelling Expense 9 monthSelling Expense 12 month
2026-06-30$3.07M
10-Q · filed 2026-08-04
$5.94M
10-Q · filed 2026-08-04
$8.86M
derived: sum of 3 quarters · filed 2026-08-04
$11.77M
derived: sum of 4 quarters · filed 2026-08-04
2026-03-31$2.87M
10-Q · filed 2026-05-06
$5.79M
derived: sum of 2 quarters · filed 2026-05-06
$8.69M
derived: sum of 3 quarters · filed 2026-05-06
$11.46M
derived: sum of 4 quarters · filed 2026-08-04
2025-12-31$2.92M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04
$5.83M
derived: sum of 2 quarters · filed 2026-03-04
$8.59M
derived: sum of 3 quarters · filed 2026-08-04
$11.26M
10-K · filed 2026-03-04
2025-09-30$2.90M
10-Q · filed 2025-11-04
$5.67M
derived: sum of 2 quarters · filed 2026-08-04
$8.33M
10-Q · filed 2025-11-04
$11.14M
derived: sum of 4 quarters · filed 2026-08-04
2025-06-30$2.77M
10-Q · filed 2026-08-04
$5.43M
10-Q · filed 2026-08-04
$8.23M
derived: sum of 3 quarters · filed 2026-08-04
$10.61M
derived: sum of 4 quarters · filed 2026-08-04
2025-03-31$2.66M
10-Q · filed 2026-05-06
$5.47M
derived: sum of 2 quarters · filed 2026-05-06
$7.84M
derived: sum of 3 quarters · filed 2026-05-06
$10.14M
derived: sum of 4 quarters · filed 2026-05-06
2024-12-31$2.81M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04
$5.18M
derived: sum of 2 quarters · filed 2026-03-04
$7.48M
derived: sum of 3 quarters · filed 2026-03-04
$9.82M
10-K · filed 2026-03-04
2024-09-30$2.38M
10-Q · filed 2025-11-04
$4.67M
derived: sum of 2 quarters · filed 2025-11-04
$7.02M
10-Q · filed 2025-11-04
2024-06-30$2.30M
10-Q · filed 2025-08-06
$4.64M
10-Q · filed 2025-08-06
2024-03-31$2.34M
10-Q · filed 2025-05-07
2023-12-31$8.81M
10-K · filed 2025-03-04

Similar stocks

Stock NameCountryMarket CapPE Ratio
USANA HEALTH SCIENCES INC (USNA)United States$0.264B-17.90
FITLIFE BRANDS, INC. (FTLF)United States$0.087B16.59
Canopy Growth Corp (CGC)$0.395B
MANNATECH INC (MTEX)United States$0.014B
NATURAL ALTERNATIVES INTERNATIONAL INC (NAII)United States$0.011B-1.16
Synergy CHC Corp. (SNYR)United States$0.001B
Functional Brands Inc. (MEHA)United States$0.001B
Tilray Brands, Inc. (TLRY)United States$0.554B-5.97
Cronos Group Inc. (CRON)$1.223B
Definium Therapeutics, Inc. (DFTX)United States$4.931B-17.87